ARHS vs LOT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARHS exhibits weak financial health per the Piotroski F-Score of 4/9, indicating marginal stability with notable red flags in profitability and liquidity. The company trades at a P/E of 14.79, below the sector average of 43.27, but this is misleading given a sharp -28.6% YoY earnings decline and negative Q/Q earnings growth. While the Graham Number ($5.66) suggests undervaluation, the intrinsic value estimate of $3.36 reflects poor growth prospects and deteriorating fundamentals. The lack of dividend, neutral insider activity, and prolonged price decline (down 42.6% over 5 years) further undermine confidence. Despite a recent analyst 'buy' recommendation, the underlying metrics suggest significant distress risk.
Lotus Technology Inc. presents a high-risk profile characterized by severe liquidity distress and collapsing growth. While the Piotroski F-Score of 5/9 suggests a 'stable' internal accounting trend, this is heavily overshadowed by a critical Quick Ratio of 0.09 and a negative Price-to-Book ratio (-0.74), indicating negative shareholder equity. With revenue plummeting by 46% both YoY and Q/Q, the company is experiencing a fundamental contraction in its business model. The combination of deep negative margins (-130.45%) and a bearish technical trend makes this a highly speculative and distressed asset.
Compare Another Pair
Related Comparisons
ARHS vs LOT: Head-to-Head Comparison
This page compares Arhaus, Inc. (ARHS) and Lotus Technology Inc. (LOT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.